85653-34-5

Basic information

• Product Name: (+)-N-benzylcinchonineammonium bromide
• Synonyms: (+)-N-benzylcinchonineammonium bromide
• CAS NO: 85653-34-5
• Molecular Weight: 465.433
• Mol File: 85653-34-5.mol
• Article Data: 7

Chemical Properties

• CAS DataBase Reference: (+)-N-benzylcinchonineammonium bromide(CAS DataBase Reference)
• NIST Chemistry Reference: (+)-N-benzylcinchonineammonium bromide(85653-34-5)
• EPA Substance Registry System: (+)-N-benzylcinchonineammonium bromide(85653-34-5)

Safety Data

• Hazardous Substances Data: 85653-34-5(Hazardous Substances Data)

Upstream product

• 100-39-0 benzyl bromide 
• 118-10-5 cinchonine 
• 118-10-5 Cinchonin 

Relevant articles and documents

Antimicrobial activity of quasi-enantiomeric cinchona alkaloid derivatives and prediction model developed by machine learning

Bacterial infections that do not respond to current treatments are increasing, thus there is a need for the development of new antibiotics. Series of 20 N-substituted quaternary salts of cinchonidine (CD) and their quasi-enantiomer cinchonine (CN) were pr

Ring-Strain-Enabled Catalytic Asymmetric Umpolung C-O Bond-Forming Reactions of 1,2-Oxazetidines for the Synthesis of Functionalized Chiral Ethers

An unprecedented catalytic asymmetric umpolung C-O bond-forming reaction of N-nosyl 1,2-oxazetidines with β-keto esters has been achieved in the presence of a chiral phase-transfer catalyst, allowing access to a range of highly functionalized chiral ethers bearing quaternary and no adjacent stereogenic centers with high yields, excellent enantioselectivities, and diastereoselectivities (up to 97percent ee and 20:1 dr). These versatile products could be flexibly transformed into biologically important chiral fused and spiro morpholines in two steps.

ENANTIOENRICHED VIRIDICATUMTOXIN B ANALOGS

In one aspect, the present disclosure provides derivatives of viridicatumtoxin of the formula wherein the variables are as defined herein. Also provided herein are compositions and methods of treating a bacterial infection, a viral infection, or in the treatment of cancer. The present disclosure also provides methods of synthesizing enantiopure viridicatumtoxin and other anthrone compounds.